Cargando…
Stereotactic Radiotherapy for Oligometastasis
Oligometastatic disease is defined as “a condition with a few metastases arising from tumors that have not acquired a potential for widespread metastases.” Its behavior suggests a transitional malignant state somewhere between localized and metastatic cancer. Treatment of oligometastatic disease is...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407034/ https://www.ncbi.nlm.nih.gov/pubmed/30678111 http://dx.doi.org/10.3390/cancers11020133 |
_version_ | 1783401463255400448 |
---|---|
author | Otake, Sotaro Goto, Taichiro |
author_facet | Otake, Sotaro Goto, Taichiro |
author_sort | Otake, Sotaro |
collection | PubMed |
description | Oligometastatic disease is defined as “a condition with a few metastases arising from tumors that have not acquired a potential for widespread metastases.” Its behavior suggests a transitional malignant state somewhere between localized and metastatic cancer. Treatment of oligometastatic disease is expected to achieve long-term local control and to improve survival. Historically, patients with oligometastases have often undergone surgical resection since it was anecdotally believed that surgical resection could result in progression-free or overall survival benefits. To date, no prospective randomized trials have demonstrated surgery-related survival benefits. Short courses of highly focused, extremely high-dose radiotherapies (e.g., stereotactic radiosurgery and stereotactic ablative body radiotherapy (SABR)) have frequently been used as alternatives to surgery for treatment of oligometastasis. A randomized study has demonstrated the overall survival benefits of stereotactic radiosurgery for solitary brain metastasis. Following the success of stereotactic radiosurgery, SABR has been widely accepted for treating extracranial metastases, considering its efficacy and minimum invasiveness. In this review, we discuss the history of and rationale for the local treatment of oligometastases and probe into the implementation of SABR for oligometastatic disease. |
format | Online Article Text |
id | pubmed-6407034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64070342019-03-21 Stereotactic Radiotherapy for Oligometastasis Otake, Sotaro Goto, Taichiro Cancers (Basel) Review Oligometastatic disease is defined as “a condition with a few metastases arising from tumors that have not acquired a potential for widespread metastases.” Its behavior suggests a transitional malignant state somewhere between localized and metastatic cancer. Treatment of oligometastatic disease is expected to achieve long-term local control and to improve survival. Historically, patients with oligometastases have often undergone surgical resection since it was anecdotally believed that surgical resection could result in progression-free or overall survival benefits. To date, no prospective randomized trials have demonstrated surgery-related survival benefits. Short courses of highly focused, extremely high-dose radiotherapies (e.g., stereotactic radiosurgery and stereotactic ablative body radiotherapy (SABR)) have frequently been used as alternatives to surgery for treatment of oligometastasis. A randomized study has demonstrated the overall survival benefits of stereotactic radiosurgery for solitary brain metastasis. Following the success of stereotactic radiosurgery, SABR has been widely accepted for treating extracranial metastases, considering its efficacy and minimum invasiveness. In this review, we discuss the history of and rationale for the local treatment of oligometastases and probe into the implementation of SABR for oligometastatic disease. MDPI 2019-01-23 /pmc/articles/PMC6407034/ /pubmed/30678111 http://dx.doi.org/10.3390/cancers11020133 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Otake, Sotaro Goto, Taichiro Stereotactic Radiotherapy for Oligometastasis |
title | Stereotactic Radiotherapy for Oligometastasis |
title_full | Stereotactic Radiotherapy for Oligometastasis |
title_fullStr | Stereotactic Radiotherapy for Oligometastasis |
title_full_unstemmed | Stereotactic Radiotherapy for Oligometastasis |
title_short | Stereotactic Radiotherapy for Oligometastasis |
title_sort | stereotactic radiotherapy for oligometastasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407034/ https://www.ncbi.nlm.nih.gov/pubmed/30678111 http://dx.doi.org/10.3390/cancers11020133 |
work_keys_str_mv | AT otakesotaro stereotacticradiotherapyforoligometastasis AT gototaichiro stereotacticradiotherapyforoligometastasis |